Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol

Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib

(2015) Andrea Casadei Gardini et al.   EXPERT OPINION ON PHARMACOTHERAPY

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management

(2014) Luca Faloppi et al.   BMC CANCER

VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study

(2014) Mario Scartozzi et al.   INTERNATIONAL JOURNAL OF CANCER

Discrepancies between VEGF −1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue

(2014) Giorgia Marisi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-Like Syndrome With Activation of the Endothelin System

(2011) Mariëtte H.W. Kappers et al.   HYPERTENSION

Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels

(2010) Mariëtte H.W. Kappers et al.   HYPERTENSION

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS